Replimune Group (NASDAQ:REPL) Posts Earnings Results, Misses Estimates By $0.03 EPS

Replimune Group (NASDAQ:REPL) issued its quarterly earnings data on Monday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.03), FiscalAI reports.

Replimune Group Price Performance

REPL opened at $11.63 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The stock has a market capitalization of $960.32 million, a PE ratio of -3.38 and a beta of 0.88. The stock’s 50 day moving average price is $6.23 and its 200-day moving average price is $7.28. Replimune Group has a 52-week low of $1.50 and a 52-week high of $13.24.

Insider Buying and Selling

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its position in Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares during the period. Raymond James Financial Inc. purchased a new stake in Replimune Group during the 2nd quarter valued at $69,000. Dynamic Technology Lab Private Ltd purchased a new stake in Replimune Group during the third quarter valued at $85,000. Finally, Tower Research Capital LLC TRC boosted its position in Replimune Group by 2,020.8% in the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after purchasing an additional 9,235 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REPL has been the subject of several research reports. HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. BMO Capital Markets lowered shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Weiss Ratings raised Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Replimune Group presently has an average rating of “Reduce” and a consensus target price of $6.00.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.